Filtered By:
Cancer: Non-Small Cell Lung Cancer
Countries: Japan Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 3 results found since Jan 2013.

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Impact of the preoperative body mass index on the postoperative outcomes in patients with completely resected non-small cell lung cancer: A retrospective analysis of 16,503 cases in a Japanese Lung Cancer Registry Study
Obesity is responsible for multiple chronic diseases, including type 2 diabetes, hypertension, coronary artery disease, stroke, and several types of cancer [1]. The body mass index (BMI) —as an easy-to obtain, acceptable proxy for thinness and fatness—has been found to be associated with health risk and death in many populations. According to the World Health Organization definition, the normal range of BMI is defined as 18.5 to
Source: Lung Cancer - September 18, 2020 Category: Cancer & Oncology Authors: Koichi Fukumoto, Shoichi Mori, Yasushi Shintani, Jiro Okami, Hiroyuki Ito, Takashi Ohtsuka, Shinichi Toyooka, Takeshi Mori, Shun-ichi Watanabe, Hisao Asamura, Masayuki Chida, Hiroshi Date, Shunsuke Endo, Takeshi Nagayasu, Ryoichi Nakanishi, Etsuo Miyaoka, Source Type: research

Coronary artery calcification scoring system based on the coronary artery calcium data and reporting system (CAC-DRS) predicts major adverse cardiovascular events or all-cause death in patients with potentially curable lung cancer without a history of cardiovascular disease
In conclusion, the CAC-DRS score on non-gated standard CT can predict incident MACEs and/or all-cause death in patients with potentially curable resected lung cancer. Lung cancer survivors with a greater CAC-DRS category may need more active management of cardiovascular risk factors.
Source: Heart and Vessels - May 21, 2020 Category: Cardiology Source Type: research